169 related articles for article (PubMed ID: 12712457)
1. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Friedman HS; Keir ST; Houghton PJ
Cancer; 2003 May; 97(9 Suppl):2359-62. PubMed ID: 12712457
[TBL] [Abstract][Full Text] [Related]
2. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Castellino RC; Elion GB; Keir ST; Houghton PJ; Johnson SP; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 2000; 45(4):345-9. PubMed ID: 10755324
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan: promising activity in the treatment of malignant glioma.
Reardon DA; Friedman HS; Powell JB; Gilbert M; Yung WK
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):9-14. PubMed ID: 12800600
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.
Patel VJ; Elion GB; Houghton PJ; Keir S; Pegg AE; Johnson SP; Dolan ME; Bigner DD; Friedman HS
Clin Cancer Res; 2000 Oct; 6(10):4154-7. PubMed ID: 11051270
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide in combination with other cytotoxic agents.
Prados M
Semin Oncol; 2001 Aug; 28(4 Suppl 13):24-33. PubMed ID: 11550136
[TBL] [Abstract][Full Text] [Related]
6. O6-benzylguanine-mediated enhancement of chemotherapy.
Friedman HS; Keir S; Pegg AE; Houghton PJ; Colvin OM; Moschel RC; Bigner DD; Dolan ME
Mol Cancer Ther; 2002 Sep; 1(11):943-8. PubMed ID: 12481416
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Coggins CA; Elion GB; Houghton PJ; Hare CB; Keir S; Colvin OM; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1998; 41(6):485-90. PubMed ID: 9554593
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
11. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Friedman HS
Cancer; 2009 Jul; 115(13):2964-70. PubMed ID: 19402172
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Reardon DA; Quinn JA; Rich JN; Gururangan S; Vredenburgh J; Sampson JH; Provenzale JM; Walker A; Badruddoja M; Tourt-Uhlig S; Herndon JE; Dowell JM; Affronti ML; Jackson S; Allen D; Ziegler K; Silverman S; Bohlin C; Friedman AH; Bigner DD; Friedman HS
Neuro Oncol; 2004 Apr; 6(2):134-44. PubMed ID: 15134628
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Kirstein MN; Poquette CA; Tan M; Friedman HS; Brent TP
Clin Cancer Res; 2000 Oct; 6(10):4110-8. PubMed ID: 11051264
[TBL] [Abstract][Full Text] [Related]
15. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
16. CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Chamberlain MC; Glantz MJ
J Neurooncol; 2008 Sep; 89(2):231-8. PubMed ID: 18480965
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Chen TC; Su S; Fry D; Liebes L
Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458
[TBL] [Abstract][Full Text] [Related]
18. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
[TBL] [Abstract][Full Text] [Related]
19. Experience with irinotecan for the treatment of malignant glioma.
Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS
Neuro Oncol; 2009 Feb; 11(1):80-91. PubMed ID: 18784279
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Quinn JA; Reardon DA; Friedman AH; Rich JN; Sampson JH; Vredenburgh J; Gururangan S; Provenzale JM; Walker A; Schweitzer H; Bigner DD; Tourt-Uhlig S; Herndon JE; Affronti ML; Jackson S; Allen D; Ziegler K; Bohlin C; Lentz C; Friedman HS
Neuro Oncol; 2004 Apr; 6(2):145-53. PubMed ID: 15134629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
